Translational Molecular Imaging in Cancer
a posse ad esse - from being possible to being actual
Head: Professor Emmet Mc Cormack
Technological advances have identified differentially expressed proteins and genes unearthing many new targets in a wide variety of cancers. However, the methods employed to authenticate these targets in vivo tend to be protracted with preclinical validation remaining the rate-limiting step. Preclinical molecular imaging of specific disease processes in clinically relevant animal models provides more intuitive data of all aspects of drug pharmacology. Thus, our group activities are to aid acceleration of new drug validation through application of novel formulations and imaging agents that provide better contrast between normal and disease pathologies. This will be achieved through the development of more relevant preclinical models of cancer and employment of different imaging modalities.
The imaging platforms at UiBs Haukeland campus, in addition to state-of-the-art preclinical facilities provides an exciting environment for research and development in the area of small animal molecular imaging.
Address: Section for Haematology, Department of Clinical Science, University of Bergen, Bergen 5021, Norway
Tel: +47 559 85364